Centre Jean Perrin   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Clermont-Ferrand France (1973)

Organization Overview

First Clinical Trial
1996
NCT00162708
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Centre Jean Perrin | Centre Jean Perrin, 63011 Clermond-Ferrand, France | Centre Jean-Perrin Clermont-Ferrand | CENTRE JEAN PERRIN - Clermont Ferrand | Centre Jean Perrin, Clermont Ferrand, France | Centre Jean Perrin CLERMONT FERRAND France

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Adenocarcinoma (Phase 3)

Breast Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Laryngeal Neoplasms (Phase 3)

Melanoma (Phase 1)

Mouth Neoplasms (Phase 3)

Neoplasm Metastasis (Phase 3)

Oropharyngeal Neoplasms (Phase 3)

Osteoarthritis, Knee (Phase 1)

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 23
  • # of Trial APIs: 25